SCHEMBL3448167

SCHEMBL3448167

CCOC(=O)c1cc(-c2cnc(Nc3cc(OC)cc(OC)c3)nc2-n2nc(C(F)(F)F)cc2C)cnc1OCCNC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.40
SIRT5 Q9NXA8 3/20 0.40
NPSR1 Q6W5P4 3/20 0.38
TYRO3 Q06418 1/20 0.36
MERTK Q12866 1/20 0.36
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
TSHR P16473 1/20 0.34
CNR2 P34972 2/20 0.34
STIM1 Q13586 1/20 0.34
ORAI1 Q96D31 1/20 0.34
DAPK1 P53355 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13312579 0.95 SIRT5 (0.41) SYKSIRT5NPSR1TYRO3MERTK
SCHEMBL3450793 0.92 SYK (0.46) SYKTYRO3MERTKCNR2STIM1
SCHEMBL3449657 0.90 NPSR1 (0.37) SYKSIRT5NPSR1TYRO3MERTK
SCHEMBL13312581 0.89 SIRT5 (0.38) SYKSIRT5NPSR1TYRO3MERTK
SCHEMBL3449065 0.89 SYK (0.39) SYKTYRO3MERTKCNR2DAPK1
Methane SCHEMBL3449659 0.87 NPSR1 (0.37) SYKSIRT5NPSR1TYRO3MERTK
SCHEMBL3373538 0.85 TYRO3 (0.39) SYKTYRO3MERTKMAPTCNR2
SCHEMBL3450610 0.83 SIRT5 (0.39) SYKSIRT5NPSR1TYRO3MERTK
SCHEMBL3450368 0.83 SYK (0.42) SYKSIRT5NPSR1TYRO3MERTK
SCHEMBL3373077 0.82 SYK (0.41) SYKTYRO3MERTKMAPTCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD SYK 804/4885SIRT5 945/4885NPSR1 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.